Timeline

  • Syntiron founded – 2004 Syntiron founded – 2004

    Syntiron founded – 2004

Syntiron founded – 2004

Syntiron LLC is founded by Life Science Innovations and Epitopix.

  • Move to UEL – 2005 Move to UEL – 2005

    Move to UEL – 2005

Move to UEL – 2005

Syntiron moves to the University Enterprise Laboraties in Saint Paul, MN.

  • Phase I NIH grant for Salmonella – 2007 Phase I NIH grant for Salmonella – 2007

    Phase I NIH grant for Salmonella – 2007

Phase I NIH grant for Salmonella – 2007

Syntiron receives its first NIH SBIR Phase I grant to develop a Salmonella vaccine for humans.

  • Phase I NIH grant for Yersinia – 2008 Phase I NIH grant for Yersinia – 2008

    Phase I NIH grant for Yersinia – 2008

Phase I NIH grant for Yersinia – 2008

Syntiron receives its second NIH SBIR Phase I grant to develop a Yersinia pestis vaccine for humans.

  • Tekne Award – 2008 Tekne Award – 2008

    Tekne Award – 2008

Tekne Award – 2008

Syntiron receives the Tekne Biotechnology Award from the Minnesota High Tech Association.

  • DTRA contract – 2008 DTRA contract – 2008

    DTRA contract – 2008

DTRA contract – 2008

Syntiron is awarded a $4.1M contract from the Defense Threat Reduction Agency (DTRA) to develop a multivalent vaccine to prevent anthrax, plague and melioidosis in collaboration with the Naval Medical Research Center (NMRC).

  • Phase I NIH grants for Staph – 2009 Phase I NIH grants for Staph – 2009

    Phase I NIH grants for Staph – 2009

Phase I NIH grants for Staph – 2009

Syntiron receives third and fourth NIH SBIR Phase I grants to study active and passive vaccines for Staphylococcus aureus.

  • Sanofi Pasteur contract – 2009 Sanofi Pasteur contract – 2009

    Sanofi Pasteur contract – 2009

Sanofi Pasteur contract – 2009

Syntiron signs a $149M research and licensing contract with Sanofi Pasteur to develop a Staphylococcus aureus vaccine for humans.

  • Master seed for E. coli – 2012 Master seed for E. coli – 2012

    Master seed for E. coli – 2012

Master seed for E. coli – 2012

Syntiron produces first master seed for manufacturing (E. coli ExPEC).

  • DTRA contract extended – 2012 DTRA contract extended – 2012

    DTRA contract extended – 2012

DTRA contract extended – 2012

DTRA extends Syntiron’s research contract to develop a Burkholderia vaccine